GAS5 and cholangiocarcinoma: GAS5 was substantially upregulated in 13 cancer types, including cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), LIHC, lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), metastatic skin cutaneous melanoma (SKCM metastasis), stomach adenocarcinoma (STAD), and thyroid carcinoma (THCA).